Enanta Pharmaceuticals, Inc. (ENTA)
13.45
+0.04
(+0.30%)
USD |
NASDAQ |
May 18, 16:00
13.44
-0.01
(-0.07%)
After-Hours: 20:00
Enanta Pharmaceuticals Research and Development Expense (Quarterly) : 19.44M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cyclerion Therapeutics, Inc. | 0.73M |
| Keros Therapeutics, Inc. | 16.10M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Amgen, Inc. | 1.719B |